Aflibercept and ranibizumab comparable in macular degeneration

NEW YORK (Reuters Health) - They're similarly effective and safe for neovascular age-related macular degeneration, but intravitreal aflibercept might have an edge over ranibizumab in convenience, researchers say.

Full Story →